Fireside Chat scheduled for Tuesday, March 15, 2022, at 9:30 a.m., PT
BOCA RATON, Fla., March 08, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today, that James Sapirstein, Chairman and Chief Executive Officer, will participate in a “fireside chat” with Jonathan Aschoff, Ph.D., Managing Director and Senior Research Analyst at Roth Capital Partners, during the 34th Annual ROTH Conference taking place March 13-15, 2022, at The Ritz Carlton, Laguna Niguel located in Dana Point, California.
During the fireside chat, Mr. Sapirstein will provide an overview of First Wave BioPharma’s business and clinical development programs and discuss anticipated 2022 milestones. Additionally, during the conference, Mr. Sapirstein and members of the First Wave BioPharma management team will be participating in virtual one-on-one meetings with registered investors and pharmaceutical companies.
Details of the fireside chat are as follows:
|Event:||34th Annual Roth Conference|
|Date:||Tuesday, March 15, 2022|
|Time:||9:30 a.m. PT to 9:55 a.m. PT (12:30 p.m. ET to 12:55 p.m. ET)|
|Location:||Healthcare VFC -- Suite 3022|
Registered conference attendees can access a livestream and replays of all fireside chats and presentations at https://www.meetmax.com/sched/event_75329/conference_invlogin.html. A live webcast of the fireside chat will be available on the company’s website at https://firstwavebio.com/investors/events.
About First Wave BioPharma, Inc.
First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company is currently advancing a therapeutic development pipeline with multiple clinical stage programs built around its two proprietary technologies – niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. First Wave BioPharma’s niclosamide portfolio is led by two clinical programs in Phase 2 clinical trials: FW-COV for COVID-19 gastrointestinal infections and FW-UP for ulcerative proctitis (UP) and ulcerative proctosigmoiditis. Three additional indications of niclosamide, include FW-ICI-AC, for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-associated colitis and diarrhea in advanced oncology patients, FW-UC (ulcerative colitis) and FW-CD (Crohn’s disease). The Company is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis. First Wave BioPharma is headquartered in Boca Raton, Florida. For more information visit www.firstwavebio.com.
This press release may contain certain statements relating to future results which are forward-looking statements. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial will be indicative of the final results of the trial; the size of the potential markets for the Company’s drug candidates and its ability to service those markets; the effects of the First Wave Bio, Inc. acquisition and its announcement on the Company’s business, operating results and financial prospects; the integration of the First Wave Bio, Inc. business with the Company’s own business; and the Company’s current and future capital requirements and its ability to raise additional funds to satisfy its capital needs. Additional information concerning the Company and its business, including a discussion of factors that could materially affect the Company’s financial results are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 under the heading “Risk Factors,” as well as the Company’s subsequent filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
For more information:
First Wave BioPharma, Inc.
777 Yamato Road, Suite 502
Boca Raton, FL 33431
Phone: (561) 589-7020
Tiberend Strategic Advisors, Inc.